This article was originally published in The Gray Sheet
Debt holder Amoco Technology Company converts a 7.9% note for $2.4 mil. plus $658,839 in interest into 428,532 shares of Quidel common stock at a $7.14 per share conversion price. The note was issued in 1990 and "would have become convertible at the option of Quidel in August of this year at the same conversion price," according to Quidel. The maker of rapid diagnostic tests announced the retirement of $4 mil. in 12% unsecured long-term debt earlier this month ("The Gray Sheet" July 19, p. 22). The firm says the two transactions increase shareholder equity by 72% over the March 31 level.
You may also be interested in...
The MHRA is in listening mode as it gathers feedback to shape the UKCA marking for medical devices. See what Phil Brown, regulatory director of the Association of British HealthTech Industries, said about it here.
Following a memorable cancer drug advisory panel meeting where FDA explained how accelerated approvals may be more at risk due to changing standard of care, ChemoCentryx’s ANCA-vasculitis treatment runs into trouble because of another drug’s changing indication during their Phase III study.
A 2008 law that limited exclusivity for certain antibiotics to three years does not apply to Allergan’s Avycaz, which combines an approved old antibiotic active moiety and a new active moiety, CDER exclusivity board concludes.